The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study

The article presents the experience of 19 Russian medical institutions on the use of eribulin in combination with trastuzumab in various treatment lines of metastatic HER2+ breast cancer in routine clinical practice. Aim. The main objective of this retrospective observational study was to evaluat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Elena I. Kovalenko, Elena V. Artamonova, Elena V. Karabina, Irina I. Andreiashkina, Ekaterina A. Prokof’eva, Nataliia O. Popova, Elena A. Gaisina, Irina V. Evstigneeva, Mikhail V. Shaidorov, Larisa A. Zhiliaeva, Dmitrii M. Ponomarenko, Alfiia I. Khasanova, Guzel Z. Mukhametshina, Anton E. Koziakov, Liudmila V. Vorotilina, Anton Iu. Povyshev, Elena I. Simolina, Vasilii V. Marfutov, Dmitrii V. Kozlov, Irina R. Suslova, Valentina E. Shikina, Tatiana V. Karandeeva, Artem O. Shepel’, Liudmila V. Kramskaia, Denis A. Oskirko, Olga S. Frolova
Formato: article
Lenguaje:RU
Publicado: IP Habib O.N. 2020
Materias:
breast cancer
eribulin
efficacy
tolerance
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/348c12ae10644482a51e5fd30b93fd11
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/348c12ae10644482a51e5fd30b93fd11

Ejemplares similares